Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal

Laiba Immad

Wed, February 18, 2026 at 3:16 PM GMT+9 2 min read

In this article:

HIMS

-0.18%

NVO

-0.40%

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.

Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best healthcare stocks on our list.

TheFly reported on February 10 that Deutsche Bank lowered its price target on HIMS to $31 from $42 and maintained a Hold rating on the shares. The firm noted that the company is “under siege” following the reversal of its GLP-1 pill launch, reflecting heightened uncertainty around its recently introduced products and near-term growth prospects.

Earlier on February 5, Novo Nordisk criticized Hims & Hers Health, Inc. (NYSE:HIMS) for planning to mass-market what it called an unapproved semaglutide pill. Novo Nordisk said it would take legal and regulatory measures to safeguard patients, protect its intellectual property, and support the U.S. drug approval system, and called the action illegal, large-scale compounding that could jeopardize patient safety. Additionally, it referenced earlier FDA warnings regarding alleged deceptive advertising and charged HIMS with pushing GLP-1 imitation goods.

On February 9, HIMS responded to Novo Nordisk’s lawsuit, calling it an attempt to limit access to compounded medications. The company restated its commitment to affordable healthcare options in a post on X, stating that the case reflected broader efforts by a major pharmaceutical manufacturer to limit consumer choice and access to tailored therapies.

Hims & Hers Health, Inc. (NYSE:HIMS) is a U.S. telehealth and wellness platform that innovates by using data‑driven technology, digital diagnostics, and personalized virtual care to connect consumers with licensed providers and tailored treatments at scale and expand access to affordable, customized health solutions.

While we acknowledge the potential of HIMS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info